Janet M Oliver Selected Research

rhuMAb-E25

1/2010

Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janet M Oliver Research Topics

Disease

3	Asthma (Bronchial Asthma) 01/2010 - 04/2007
2	Leukemia 02/2010 - 03/2007
2	Inflammation (Inflammations) 01/2010 - 04/2003
1	Hypersensitivity (Allergy) 01/2013
1	Disease Resistance 12/2008
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2008
1	Breast Neoplasms (Breast Cancer) 08/2007

Drug/Important Bio-Agent (IBA)

3	IgE Receptors (Fc epsilon RI)IBA 01/2013 - 04/2003
3	Immunoglobulin E (IgE)IBA 02/2010 - 01/2010
2	LigandsIBA 02/2010 - 03/2007
1	LipidsIBA 02/2010
1	rhuMAb-E25IBA 01/2010
1	Omalizumab (Xolair)FDA Link 01/2010
1	AllergensIBA 01/2010
1	CytokinesIBA 01/2010
1	ChemokinesIBA 01/2010
1	Protein Isoforms (Isoforms)IBA 12/2008
1	ErbB Receptors (EGF Receptor)IBA 08/2007
1	Histamine (Histamine Dihydrochloride)FDA Link 04/2007
1	Fossil Fuels (Fossil Fuel)IBA 04/2003
1	Environmental Pollutants (Pollutants, Environmental)IBA 04/2003

Therapy/Procedure

3	Therapeutics 01/2010 - 12/2008